Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2007-01-02
2007-01-02
Tate, Christopher (Department: 1655)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C424S208100
Reexamination Certificate
active
10050655
ABSTRACT:
The present invention relates to hyaluronidase enzyme methods, vaccines and compositions for treating or preventing pathogenic infections, such as HIV, in a patient. The invention also relates to methods, vaccines and compositions for providing immunity against HIV infection in a patient comprising treating the patient with HIV virus or HIV infected cells that have been treated with hyaluronidase.
REFERENCES:
patent: 5079236 (1992-01-01), Drizen et al.
patent: 5529987 (1996-06-01), Gallina
patent: 5550112 (1996-08-01), Gallina
patent: 5583118 (1996-12-01), Gallina
patent: 5583119 (1996-12-01), Gallina
patent: 5583120 (1996-12-01), Gallina
patent: 5624915 (1997-04-01), Gallina
patent: 5631242 (1997-05-01), Gallina
patent: 5679655 (1997-10-01), Gallina
patent: 5897880 (1999-04-01), Drizen et al.
patent: 6007843 (1999-12-01), Drizen et al.
patent: 6063405 (2000-05-01), Drizen et al.
patent: 6120804 (2000-09-01), Drizen et al.
patent: 6335034 (2002-01-01), Drizen et al.
patent: 6335035 (2002-01-01), Drizen et al.
patent: 6346271 (2002-02-01), Drizen et al.
patent: 6387407 (2002-05-01), Drizen et al.
patent: 6797267 (2004-09-01), Horwitz
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York entire document especiall p. 4).
Guo, (The Role of CD$$ in HIV), Dissertation Abstracts International, (1996), vol. 57, No. 1B, p. 255).
Francis Szoka, et al., “Mechanism of Targeting to CD44 Positive Breast Tumors”, University of California, San Francisco—School of Pharmacy, Abstract p. # A-13.
Pruimboom, et al., “Capsular Hyaluronic Acid-mediated Adhesion ofPasteurella multocidato Turkey Air Sac Macrophages”, Avian Disease, 1996, vol. 40, pp. 887-893.
H. L. Kain, “Experimentelle Untersuchungen zur proliferativen Vitreoretinopathie (PVR)”, Fortschr Ophthalmol, 1991, vol. 88, pp. 671-676.
Stanescu et al., “Interaction Between macrophages And Articular Surfaces: An In Vitro Transmission And Scanning Electron Microscopy Study”, Connective Tissue Research, 1990, vol. 24, pp. 207-218.
Shannon et al., “Participation of Hyaluronic Acid In The Macrophage Disappearance Reaction”, Immunological Communications, 1980, vol. 9, No. 4, pp. 357-370.
Sun, et al., “Expression Profile of Hyaluronidase mRNA Transcripts in the Kidney and in Renal Cells”, Kidney blood Press Research, 1998, vol. 21, pp. 413-418.
Van der Gaag, et al., “The Influence Of High Molecular Weight Sodium Hyaluronate (Healon®) On The Production Of Migration Inhibitory Factor”, IRL Press Limited, 1987, vol. 6, pp. 1433-1440.
Culty, et al., “The Hyaluronan Receptor (CD44) Participates in the Uptake and Degradation of Hyaluronan”, The Journal of Cell Biology, vol. 116, No. 4, Feb. 1992, pp. 1055-1062.
Poermadjaja, et al., “Phagocytic Uptake and Killing of Virulent And Avirulent Strains ofPasteurella Multocidaof Capsular Serotype A By Chicken Macrophages”, Veterinary Microbiology, 2000, vol. 72, pp. 163-171.
Khaldoyanidi et al., “Hyaluronate-Enhanced Hematopoiesis: Two Different Receptors Trigger the Release of Interleukin-1β and Interleukin-6 From bone Marrow Macrophages”, Blood, Aug. 1, 1999, vol. 94, No. 3, pp. 940-949.
De Carvalho et al., “Effect of Various Digestive Enzymes On The Interaction of Toxoplasma Gondii With Macrophages”, Parasitol Research, 1993, vol. 79, pp. 114-118.
Denhardt, et al., “Osteopontin As A Means To cope With Environmental Insults: Regulation Of Inflammation, Tissue Remodeling, And Cell Survival”, The Journal of Clinical Investigation, May 2001, vol. 107, No. 9, 1055-1061.
Denhardt, et al., “Role of Osteopontin In Cellular Signaling And Toxicant Injury”, Annual Review of Pharmacology and Toxicology, 2001, vol. 41, pp. 723-749.
Leite-de-Moraes, et al., “Natural Killer T Cells: A Potent Cytokine-Producing Cell Population”, European Cytokine Network, Sep. 1997, vol. 8, Issue 3, pp. 229-237.
Oswald, et al., “Tumor Necrosis Factor Is Required For The Priming of Peritoneal Macrophages By Trehalose Dimycolate”, European Cytokine Network, Dec. 1999, vol. 10, Issue 4, pp. 533-540.
McDonnell Boehnen & Hulbert & Berghoff LLP
Surrogate Pharmaceutical Pathways, LLC
Tate Christopher
Winston Randall
LandOfFree
Compositions and methods for treating retroviral infections does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating retroviral infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating retroviral infections will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3730180